Does Kaiser Permanente Cover GLP-1 Medications in 2026?
Introduction
Kaiser Permanente operates as an integrated HMO across 9 regions: California (Northern and Southern), Colorado, Georgia, Hawaii, Maryland, Oregon, Virginia, Washington, and the District of Columbia. The insurance plan, the medical group, and the pharmacy benefit are all the same organization. That structure shapes GLP-1 coverage in a distinctive way.
Kaiser’s 2026 formulary covers GLP-1 medications, but the PA criteria are stricter than most commercial plans. Kaiser’s regional P&T committees have historically restricted Wegovy® and Zepbound® to patients meeting BMI 35 or higher (or 30 with severe comorbidity), with a 12-month weight management program requirement rather than the typical 6 months at most commercial plans. The integrated system uses internal Kaiser weight management services as the primary qualifying program.
The cardiovascular indication for Wegovy, FDA-approved in March 2024 after the SELECT trial (Lincoff et al. 2023, NEJM) showed 20 percent MACE reduction, opened a separate pathway on Kaiser plans with relaxed criteria. The OSA indication for Zepbound, FDA-approved in December 2024 after SURMOUNT-OSA, opened another.
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.
Which GLP-1 Medications Does Kaiser Cover?
Kaiser’s 2026 formulary includes six GLP-1 medications: Wegovy (semaglutide for obesity and CVD), Zepbound (tirzepatide for obesity and OSA), Ozempic® (semaglutide for type 2 diabetes), Mounjaro® (tirzepatide for type 2 diabetes), Saxenda® (liraglutide for obesity), and Rybelsus® (oral semaglutide for type 2 diabetes).
Quick Answer: Kaiser Permanente is an integrated HMO; its internal P&T committee writes PA criteria, not an external PBM
Diabetes coverage is consistent across plans. Ozempic and Mounjaro are covered for type 2 diabetes with PA on every Kaiser plan. The PA requires recent A1C of 7.0 or higher and prior metformin trial unless contraindicated.
Obesity coverage on Kaiser is stricter than most commercial plans. Wegovy and Zepbound are restricted by tighter BMI criteria, longer weight management program requirements, and step therapy. Whether they’re covered also depends on whether the employer group included weight-loss drugs in the benefit design.
What Is Kaiser’s 2026 Prior Authorization for Wegovy?
Kaiser’s 2026 PA criteria for Wegovy vary by region but generally require BMI of 35 or higher, or BMI 30 to 34.9 with at least one severe weight-related comorbidity (type 2 diabetes, severe OSA, severe hypertension, dyslipidemia with documented CVD risk), documentation of a structured weight management program through Kaiser for at least 12 months, prescriber attestation of inadequate response to lifestyle modification, and age 18 or older.
Note the differences from typical commercial PA: BMI threshold is 35 (versus 30 at most commercial plans), the comorbidity threshold at BMI 30 to 34.9 requires a severe comorbidity (not just any comorbidity), and the weight management program is typically 12 months (versus 6).
The cardiovascular indication added in 2024 has separate, looser criteria: established CVD (prior MI, ischemic stroke, or symptomatic PAD) plus BMI of 27 or higher. The 12-month weight management program requirement is waived under the CV pathway.
What Is Kaiser’s 2026 Prior Authorization for Zepbound?
Zepbound PA criteria at Kaiser mirror Wegovy in 2026, with the same BMI thresholds and 12-month program requirement. Most Kaiser plans also require step therapy with Wegovy or an older agent before approving Zepbound.
The SURMOUNT-1 trial (Jastreboff et al. 2022, NEJM) showed 20.9 percent weight loss at 72 weeks, which Kaiser’s P&T committee references when evaluating medical necessity. SURMOUNT-2 (Garvey et al. 2023, Lancet) shows 15.7 percent weight loss in patients with type 2 diabetes.
For the OSA indication after SURMOUNT-OSA, criteria are different: confirmed AHI of 15 or higher on polysomnography plus BMI of 30 or higher. The 12-month weight management program is usually waived under the OSA pathway. Most Kaiser regions added the OSA pathway in 2026.
Does Kaiser Cover Ozempic and Mounjaro?
Yes, for type 2 diabetes. Both are on formulary for every Kaiser plan in 2026, typically Tier 2 or 3 with PA.
The PA for Ozempic requires type 2 diabetes diagnosis with ICD-10 documentation, A1C of 7.0 or higher (or 6.5 to 6.9 with prior metformin trial), and age 18 or older. The SUSTAIN trial program (multiple Lancet and NEJM publications 2017 through 2019) is the clinical reference.
Mounjaro PA is similar, with the SURPASS trial program as the reference. SURPASS-2 (Frias et al. 2021, NEJM) showed A1C reductions of 2.0 to 2.3 percentage points at the highest dose, the strongest A1C lowering of any approved diabetes drug.
Kaiser does not cover off-label Ozempic or Mounjaro for weight loss. Without a type 2 diabetes diagnosis, these will be denied for obesity treatment.
What If I Have a Kaiser Medicare Advantage Plan?
Kaiser Medicare Advantage plans cover Wegovy only for the cardiovascular indication after the March 2024 CMS coverage update. Wegovy is not covered for weight loss alone under Medicare. The PA requires established CVD with ICD-10 documentation and BMI of 27 or higher.
Zepbound is not covered for obesity under Medicare Part D as of 2026. Some Kaiser MA plans cover Zepbound for the OSA indication after the December 2024 approval, but this varies by plan and regional benefit design.
Ozempic and Mounjaro are covered for type 2 diabetes across all Kaiser MA plans.
Key Takeaway: The cardiovascular indication for Wegovy and the OSA indication for Zepbound are separate pathways with relaxed criteria
What About Kaiser Employer Group Plans?
Kaiser administers employer group plans through fully-insured arrangements (Kaiser self-insures most of its book). The benefit design includes either a weight-loss drug benefit or an exclusion. Many large employer groups have included weight-loss drug coverage in their Kaiser plans starting in 2024 and 2025 as GLP-1 coverage became a benefits competitive issue.
Self-funded employer groups administered by Kaiser through ASO arrangements can exclude weight-loss drugs. The carve-out applies to obesity coverage in most cases. The cardiovascular indication for Wegovy and the OSA indication for Zepbound may be covered separately because they are not obesity-coverage line items.
Diabetes coverage for Ozempic and Mounjaro is rarely carved out.
What If Kaiser Denies My GLP-1 Prescription?
Pull your Kaiser denial letter and find the reason. The most common codes are PA-NOT-MET, BMI-NOT-MET, PROGRAM-MISSING (missing 12-month weight management documentation), STEP-REQ, and EMP-EXCL.
For PA-NOT-MET denials, file a level-1 internal appeal within 180 days. Include a Letter of Medical Necessity from your Kaiser prescriber citing STEP 1 (Wilding et al. 2021, NEJM) for Wegovy or SURMOUNT-1 (Jastreboff et al. 2022, NEJM) for Zepbound. Add documentation of the Kaiser weight management program by name and date.
For an Independent Medical Review (IMR), file with the California DMHC (for California Kaiser members) or your state insurance commissioner. The IMR is independent of Kaiser and decisions are binding. Approval rates run around 50 percent for prescription drug denials.
How Much Do GLP-1 Medications Cost with Kaiser?
With PA approved on Tier 3, expect a copay of $40 to $100 per month, depending on your specific plan. Kaiser high-deductible plans charge the full negotiated rate (around $900 to $1,000) until the deductible is met.
For Kaiser Medicare Part D coverage, the 2026 Part D out-of-pocket cap of $2,000 per year applies. Total annual spending on a covered GLP-1 won’t exceed that cap.
Without coverage, brand-name Wegovy lists at about $1,349 per month. The NovoCare savings card can bring eligible commercially-insured patients to $0 to $25 per month, and the NovoCare Pharmacy direct cash program offers Wegovy at about $499 per month for cash-pay patients. Brand-name Zepbound lists at about $1,059 per month, with LillyDirect at $349 to $499 per month for vials.
What Is the Appeal Process Timeline?
A standard level-1 internal appeal at Kaiser takes 30 days. A level-2 takes another 30 days. An Independent Medical Review through the state regulator typically takes 45 to 60 days but can be expedited to 7 days.
Full timeline through every level: roughly 4 to 5 months from initial denial to a final IMR decision. Expedited appeals can compress to 10 to 14 days end to end.
Expedited appeals require prescriber attestation that delay would seriously jeopardize health. Triggers include uncontrolled diabetes, established CVD, severe OSA, or recent cardiovascular events.
Bottom line: Ozempic and Mounjaro are covered for type 2 diabetes across all Kaiser plans
FAQ
Does Kaiser Cover Wegovy for Weight Loss in 2026?
Most Kaiser plans cover Wegovy for obesity with PA if you meet the BMI 35 or higher threshold (or 30 with severe comorbidity) and complete 12 months of Kaiser weight management. Coverage also depends on whether your employer group included weight-loss drugs in the benefit design.
Why Does Kaiser Cover Ozempic but Not Wegovy on My Plan?
Ozempic is covered for type 2 diabetes, a near-universal benefit. Wegovy is covered for obesity with stricter Kaiser PA criteria and is subject to employer carve-outs. Same active ingredient, different FDA indications, different coverage logic.
Does Kaiser Cover Compounded Semaglutide?
No. Kaiser and most other insurers do not cover compounded GLP-1 medications because they are not FDA-approved finished products. Compounded semaglutide is paid out of pocket through licensed 503A pharmacies, with prescriptions written by outside telehealth providers like TrimRx after a clinical assessment.
How Do I Check If My Kaiser Plan Covers Wegovy?
Log into kp.org and search the drug formulary for Wegovy. Look at the tier and check PA, step therapy, and quantity limits. Your Kaiser primary care physician can also check coverage in HealthConnect at your appointment. PA criteria are region-specific, so confirm your region’s exact requirements.
Does Kaiser Cover Zepbound for Sleep Apnea?
After the FDA approved Zepbound for moderate-to-severe OSA in December 2024, most Kaiser regions added an OSA coverage pathway in 2026. PA requires confirmed AHI of 15 or higher on polysomnography and BMI of 30 or higher. The 12-month weight management program is usually waived under the OSA pathway.
What Is the Appeal Success Rate for Kaiser GLP-1 Denials?
CMS data from 2023 shows roughly 38 to 41 percent of commercial denials are overturned on level-1 internal appeal when new documentation is submitted. IMR approval rates run around 50 percent for prescription drug denials.
Can I Get Wegovy Through Kaiser If I Have Prediabetes but Not Diabetes?
Prediabetes alone is not a qualifying severe comorbidity under Kaiser PA criteria. You would need BMI of 35 or higher to qualify on BMI alone, or BMI 30 to 34.9 plus a documented severe comorbidity. Some Kaiser regions accept metabolic syndrome as a qualifying comorbidity with documented criteria.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.
Related Articles
Transforming Lives, One Step at a Time
Keep reading
GLP-1 Medications for Men Over 40: Testosterone, Metabolism, and Results
Weight loss for men over 40 operates under a different set of biological conditions than it did in your 20s or 30s, and GLP-1…
Long-Term Weight Loss Success on GLP-1: Habits That Actually Stick
GLP-1 medications are among the most effective weight loss tools ever developed, but they don’t produce identical long-term outcomes for everyone who takes them….
GLP-1 Maintenance vs Active Weight Loss: How Dosing Strategy Changes
Most of the conversation around GLP-1 medications focuses on the active weight loss phase: how fast results come, what side effects to expect, and…
